皇冠体育app

Updated safety and educational materials are now available to support the implementation of the regulatory measures announced in the November 2023 National Patient Safety Alert and the September 2024 Drug Safety Update. 皇冠体育appy鈥�

• 皇冠体育apprapeutic area: General practice and 5 others
• Published: 10 June 2025

Psychological side effects such as anxiety, low mood, sleep disturbance, poor concentration, and forgetfulness have been infrequently reported in people with cystic fibrosis treated with Kaftrio. Healthcare professionals sho鈥�

• 皇冠体育apprapeutic area: General practice and 2 others
• Published: 7 May 2025

Healthcare professionals and patients are reminded of the risk of severe asthma attacks and increased mortality associated with overuse of SABA with or without anti-inflammatory maintenance therapy in patients with asthma. H鈥�

• 皇冠体育apprapeutic area: General practice and 2 others
• Published: 24 April 2025

Fezolinetant treatment is associated with a risk of drug induced liver injury. New recommendations have been introduced to minimise this risk. Liver function should be monitored before and during treatment in all patients ta鈥�

• 皇冠体育apprapeutic area: Dispensing GP practices and 2 others
• Published: 10 April 2025